The guardian’s recent article “Ebola treatment using antibody from survivor’s blood passes first trial” describes the therapeutic use of an antibody isolated from Ebola survivor’s blood (read more). This example emphasizes the utility of human derived antibodies; one of the goals of huMemoMABâ„¢ development is to provide a significantly more efficient tool set to the community to more efficiently tackle such diseases in the future.